Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.38 +3.57%

+$0.06 today

Market cap
$193.57M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.43M

Average 1.03M

IKT Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Inhibikase Therapeutics, Inc.NASDAQ: IKT

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$89.65M, compared with $16.95M a year earlier. Trailing-twelve-month net change in cash was -$23.87M.

Context

  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$89.65M or moves back toward the trailing-twelve-month quarterly average of -$5.97M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$89.65M-188.8% QoQ
Last fiscal yearDec 2025
$82.73M+74.8% YoY
LTMMar 2026
-$23.87M-133.6% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-628.9%——
1 year+74.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
82.73M USD
Year-over-year change
+74.8%
4-year CAGR
+32.6%

Net Change in Cash vs competitors

How IKT compares with its peers on the latest reported figures

  • IKT's LTM Mar 2026 net change in cash of $23.87M is the largest of the 8 companies compared; the peer median is $7.76M.
  • Its year-over-year change of -133.6% is the 5th highest of 7, against a peer median of +24.7%.
IKT Competitors Peer median
Net Change in Cash for IKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$23.87M -133.6%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$14.8M +181.1%——
AGENAgenus Inc.LTM Mar 2026$14.59M +142.4%-31.9%11.8%
TTRXTurn Therapeutics Inc.LTM Mar 2026$11.22M ———
ENTXEntera Bio Ltd.LTM Mar 2026$8.65M -175.8%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$7.76M +381.4%——
EXOZeXoZymes, Inc.LTM Mar 2026$7.07M -184.2%——
SRZNSurrozen, Inc.LTM Mar 2026$5.27M -92.9%—70.3%
Peer median (excluding IKT) $7.76M+24.7%-31.9%41.0%

Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Depreciation & Amortization06.72K177.4K26.27K60.5K
Deferred Income Tax00000
Stock-Based Compensation1.53M458.15K500.15K8.14M15.31M
Change in Working Capital(1.76M)171.18K234.76K204.93K55.93K
Accounts Receivables(110.14K)70.26K39.88K00
Inventory1.3M0000
Accounts Payables(630.9K)61.4K(504.41K)271.78K146.83K
Other Working Capital(2.33M)39.53K699.28K(66.85K)(90.9K)
Other Non-Cash Items721.63K67K31.54K05.05M
Operating Cash Flow(14.3M)(17.35M)(18.09M)(19.15M)(27.79M)
Capital Expenditures1(243.26K)(14.24K)0(13.4K)
Acquisitions (Net)0243.26K000
Purchases of Investments0(20.73M)(29.43M)(60.46M)(39.09M)
Sales of Investments04.96M41.1M23.45M41.6M
Other Investing Activities0(243.26K)000
Investing Cash Flow0(16.01M)11.66M(37M)2.05M
Debt Repayment(42.53K)(248.91K)000
Common Stock Issued41.14M44.14K8.54M103.48M108.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8480000
Financing Cash Flow41.09M(204.77K)8.41M103.48M108.46M
Effect of Forex Changes00000
Net Change in Cash26.8M(33.56M)1.98M47.33M82.73M
Free Cash Flow(14.3M)(17.59M)(18.1M)(19.15M)(27.79M)

Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.